Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesSyntara Ltd

Syntara Ltd

Healthcare Drug Manufacturers - Specialty & Generic
PortfolioPortfolio WatchlistWatchlist
Company price
0.018 AUD 0.00(0%)
Last update at 2026-11-05T22:59:00Z
VOLUME
84582
Market Cap
35.36M

Momentum Score

…

Syntara Limited, a clinical-stage drug development company, that targets extracellular matrix dysfunction through amine oxidase chemistry and other technologies to develop novel medicines for blood cancers and conditions linked to inflammation and fibrosis in Australia. Its lead product candidate is amsulostat, which has completed Phase 2a clinical trial for the treatment of bone marrow cancer myelofibrosis, as well as in Phase 1c/2 clinical trial for patients with myelodysplastic syndrome and in Phase 1/2 clinical trial to treat pancreatic cancer. The company also develops topical pan-LOX inhibitors with SNT-9465, which is in a Phase 1a/b study for hypertrophic scars; SNT-6302 for the treatment of keloid scars; and SNT-4728 to treat sleep behaviour disorders and slow progression of neurodegenerative diseases by reducing neuroinflammation. In addition, it develops other drug candidates to treat fibrotic and inflammatory diseases, including kidney fibrosis, MASH, pulmonary fibrosis, and cardiac fibrosis. The company has a collaboration agreement with the University of Western Australia to studying SNT-6302 in keloid scars. The company was formerly known as Pharmaxis Ltd and changed its name to Syntara Limited in December 2023. Syntara Limited was incorporated in 1998 and is headquartered in Frenchs Forest, Australia.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.02
Low
0.02
High
52 Week Price Range
0.02
Low
0.04
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Public information on Syntara Ltd (SNT.AU) is limited, and available disclosures do not clearly describe its operating business or market focus. Because of sparse reporting, any long-term growth drivers would depend on management articulating a credible strategy, achieving scalable revenue, and securing funding, which may benefit investors if executed well.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
0.02
Dividend Yield
-
Revenue TTM
6.93M
Revenue Per Share
0.00
Gross Profit TTM
-0.45M
Debt / Equity
-
ROE
-59.65%
Net Debt
-13.56M
ROCE
-100.49%
Diluted EPS TTM
-0.01

Insight News

View All

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Type yearly yearly yearly yearly yearly
Date 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Income before tax -14.35M -12.26M -13.67M -11.36M -1.94M
Net income -9.00M -7.92M -15.14M -11.36M -1.94M
Selling general administrative - 16.01M 10.07M 15.83M 14.84M
Gross profit -0.15M - - 3.06M 7.43M
Reconciled depreciation - - 0.23M 1.85M 3.24M
Ebit -16.35M - - - -
Ebitda -16.21M - - - -
Depreciation and amortization 0.15M - - - -
Operating income -16.35M -12.39M -19.49M -25.29M -22.77M
Other operating expenses 16.35M - - - -
Interest expense - - 0.39M 0.22M 13.46M
Tax provision - - 0.00M 0.00M 0.00M
Interest income - -0.01M 0.09M 0.12M 0.16M
Net interest income - - -0.30M -0.11M 13.61M
Extraordinary items - 4.34M - - -
Income tax expense -4.73M - - - -
Total revenue - 7.48M - 5.76M 7.43M
Total operating expenses 16.21M 19.87M - - -
Cost of revenue 0.15M - - 2.71M -
Total other income expense net 2.00M - 6.12M 14.03M 7.22M
Net income from continuing ops - - -13.67M -11.36M -1.94M
Net income applicable to common shares - -7.92M - - -
Breakdown 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Type yearly yearly yearly yearly yearly
Date 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Total assets 19.14M 21.44M 10.38M 24.03M 25.19M
Intangible assets 0.13M 0.15M 0.17M 0.68M 1.02M
Other current assets 0.42M 0.00M 0.35M - -
Total liab 2.92M 5.42M 5.70M 14.47M 14.38M
Total stockholder equity 16.21M 16.02M 4.68M 9.56M 10.80M
Other current liab 1.51M - 0.47M 0.28M 0.26M
Common stock 427.38M 417.88M - - -
Capital stock - - 399.32M 389.70M 380.44M
Retained earnings -414.00M -401.87M -419.60M -404.45M -393.09M
Other assets - 0.15M - - -
Cash 13.56M 15.08M 3.52M 9.23M 8.94M
Total current liabilities 2.86M 5.34M 5.45M 8.03M 6.10M
Current deferred revenue 0.12M - - - -
Net debt -13.56M - - - -
Short term debt - 0.00M - - -
Property plant equipment - 0.18M - - -
Total current assets 18.81M 20.96M 9.77M 18.68M 19.23M
Net receivables 4.83M 0.01M - 0.98M 2.46M
Inventory - - - 1.64M 2.34M
Accounts payable 1.23M - 0.61M 1.58M 0.61M
Accumulated other comprehensive income 2.84M - - - -
Non currrent assets other 0.14M - - - -
Non current assets total 0.33M - 0.61M 5.35M 5.95M
Capital lease obligations - - 0.23M 2.04M 4.29M
Long term debt total - 0.00M - - -
Breakdown 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Type yearly yearly yearly yearly yearly
Date 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Investments - - 1.49M -0.13M -0.31M
Total cashflows from investing activities -0.00M 4.18M - - -
Total cash from financing activities 8.26M 18.46M 7.20M 6.98M 6.63M
Net income -9.61M - -15.14M -11.36M -1.93M
Change in cash -1.51M 11.56M -5.80M -0.43M -9.78M
Begin period cash flow 15.08M 3.52M 9.23M 8.94M 18.71M
End period cash flow 13.56M 15.08M 3.52M 9.23M 8.94M
Total cash from operating activities -9.78M - - - -
Issuance of capital stock - - 10.00M 10.00M 9.74M
Depreciation 0.15M - - - -
Other cashflows from investing activities - 3.34M - - -
Change to account receivables -0.05M - - - -
Sale purchase of stock - -1.35M -0.68M -0.74M -0.67M
Other cashflows from financing activities -0.09M -0.18M - - -
Capital expenditures 0.00M 0.00M 0.01M 0.14M 0.31M
Change in working capital -1.21M - - - -
Other non cash items 0.90M - - - -
Free cash flow -9.78M -11.12M -14.49M -7.42M -16.41M

Peer Comparison*

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic

Stock Name
Change
(AUD)
Price
(AUD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
SNT
Syntara Ltd		 -
-%		 0.02 - 20.45 5.10 2.18 6.32 -2.16
AFP
Aft Pharmaceuticals Ltd		 -
-%		 3.59 29.92 18.18 1.48 4.37 2.05 18.56
VLS
Vita Life Sciences Ltd		 -
-%		 2.70 13.50 42.73 1.52 2.62 1.19 7.17
LGP
Little Green Pharma Ltd		 -
-%		 0.06 - 10.00 0.64 0.60 1.25 19.47
MVP
Medical Developments International Ltd		 -
-%		 0.40 40.00 166.67 1.06 0.79 0.57 7.45

Profile*

Syntara Ltd

Syntara Limited, a clinical-stage drug development company, that targets extracellular matrix dysfunction through amine oxidase chemistry and other technologies to develop novel medicines for blood cancers and conditions linked to inflammation and fibrosis in Australia. Its lead product candidate is amsulostat, which has completed Phase 2a clinical trial for the treatment of bone marrow cancer myelofibrosis, as well as in Phase 1c/2 clinical trial for patients with myelodysplastic syndrome and in Phase 1/2 clinical trial to treat pancreatic cancer. The company also develops topical pan-LOX inhibitors with SNT-9465, which is in a Phase 1a/b study for hypertrophic scars; SNT-6302 for the treatment of keloid scars; and SNT-4728 to treat sleep behaviour disorders and slow progression of neurodegenerative diseases by reducing neuroinflammation. In addition, it develops other drug candidates to treat fibrotic and inflammatory diseases, including kidney fibrosis, MASH, pulmonary fibrosis, and cardiac fibrosis. The company has a collaboration agreement with the University of Western Australia to studying SNT-6302 in keloid scars. The company was formerly known as Pharmaxis Ltd and changed its name to Syntara Limited in December 2023. Syntara Limited was incorporated in 1998 and is headquartered in Frenchs Forest, Australia.

20A Rodborough Road, Frenchs Forest, NSW, Australia, 2086

61 2 9454 7200

https://syntaratx.com.au

21

Name Title Year Born
Mr. Gary Jonathan Phillips BPharm, MBA CEO, MD & Director 1961
Mr. David Morris McGarvey BA, CA, CPA CFO & Company Secretary 1956
Dr. Wolfgang G. Jarolimek B.Sc. Ph.D., Ph.D. Head of Drug Discovery 1964
Ms. Kristen Morgan B.Sc., BSc, MMedSc, PGDipBusAdmin Head of Medical & Regulatory Affairs - Alliance Management 1972
Mr. Gary Jonathan Phillips BPharm, MBA CEO, MD & Director 1961
Mr. David Morris McGarvey BA, CA, CPA CFO & Company Secretary 1956
Dr. Wolfgang G. Jarolimek B.Sc. Ph.D., Ph.D. Head of Drug Discovery 1964
Mr. Gary Jonathan Phillips BPharm, MBA CEO, MD & Director 1961
Mr. David Morris McGarvey BA, CA, CPA CFO & Company Secretary 1956
Dr. Wolfgang G. Jarolimek B.Sc. Ph.D., Ph.D. Head of Drug Discovery 1964

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

ITH
CAD 2.15
+27.68%
HG
CAD 4.11
+19.13%
PPTA
CAD 27.74
+17.99%
UCU
CAD 2.10
+17.32%
GAU
CAD 3.49
+16.72%
TSU
CAD 29.67
-29.71%
PXT
CAD 19.73
-16.91%
LAS-A
CAD 230.50
-9.25%
IFP
CAD 13.50
-8.35%
NFI
CAD 24.01
-7.80%

Equity Sectors*

  • Basic Materials

    +3.74%

  • Communication Services

    +0.56%

  • Consumer Cyclical

    -0.34%

  • Consumer Defensive

    +0.11%

  • Energy

    +1.33%

  • Financial Services

    -0.26%

  • Healthcare

    +2.54%

  • Industrials

    -0.11%

  • Real Estate

    -0.23%

  • Technology

    +1.91%

  • Utilities

    +1.05%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…